ArticleNature communications2026
An RNase domain-dependent microRNA detection with DNA-spiked nanocage for accurate cancer diagnosis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated microRNAs are promising biomarkers for early cancer diagnosis. However, current microRNA detections - which are based on polymerase chain reaction, microarray analysis, Raman scattering, or various electrochemical assays - rely on multi-step analysis including amplification of microRNA and/or read-out signals, often causing inaccuracy despite using elaborate instruments, which remains a major challenge. Here, we describe an RNaseH1-dependent, amplification-free detection of microRNAs, which is based on Förster resonance energy transfer (FRET) between donor (single-stranded DNA probe (ssDNA)-spiked, green fluorescent nanocage) and acceptor (RNaseH1-linked, orange fluorescent protein) and enables reliable cancer diagnosis with high accuracy for human lung and gastric cancer patients and healthy donors by directly quantifying serum microRNA targets. Notably, unlike traditional ensemble FRET, this FRET platform senses molecular interactions between ssDNA and miRNAs and conformational changes of their hybrid helices and thus differentiates even a single-base mismatch, which holds significant promise for reliable, clinical cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.